Advertisement

Triclosan: A review of effectiveness and safety in health care settings

      Abstract

      Triclosan is a widely accepted antimicrobial ingredient because of its safety and antimicrobial efficacy. Triclosan is a unique antimicrobial well suited for use in the health care industry in which mildness is a necessity to protect the health care worker during repeated use and antimicrobial activity is a necessity to protect public health. Triclosan has demonstrated immediate, persistent, broad-spectrum antimicrobial effectiveness and utility in clinical health care settings. This review highlights the utility and effectiveness of a 1% triclosan formulation for use in high-risk, high-frequency handwashing. (AJIC Am J Infect Control 2000;28:184-96.)
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to American Journal of Infection Control
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bhargava HN
        • Leonard PA.
        Triclosan: applications and safety.
        AJIC Am J Infect Control. 1996; 24: 209-218
        • Ciba-Geigy Corporation
        Irgasan7DP300: Broad Spectrum Antimicrobial.
        Ciba-Geigy Corporation, High Point (NC)April, 1995
        • DeSalva SJ
        • Kong BM
        • Lin YJ.
        Triclosan: a safety profile.
        Am J Dentistry. 1989; 2: 185-196
        • Larson EL.
        American Practitioners of Infection Control guidelines for infection control practice: guideline for use of topical antimicrobial agents.
        AJIC Am J Infect Control. 1988; 16: 253-266
        • Larson EL.
        American Practitioners of Infection Control guidelines for infection control practice: APIC guideline for hand washing and hand antisepsis in health care settings.
        AJIC Am J Infect Control. 1995; 23: 251-269
        • Reybrouck G.
        Hand washing and hand disinfection.
        J Hosp Infect. 1986; 8: 5-23
        • Ciba-Geigy Corporation
        Irgasan7 DP300: Physical and Chemical Parameters.
        (Document No. 2514E)May 11, 1991
        • Food and Drug Administration
        OTC topical antimicrobial products and drug and cosmetic products proposed rules.
        39 Federal Register. September 6, 1974; : 33102-33141
        • Food and Drug Administration
        Topical antimicrobial products tentative final monograph.
        43 Federal Register. January 6, 1978; : 1210-1249
        • Food and Drug Administration
        Tentative final monograph for health-care antiseptic drug products; proposed rule.
        59 Federal Register. June 17, 1994; : 31402-31451
        • Food and Drug Administration
        FDA approves first toothpaste for gum disease.
        FDA Talk Paper. 1997 July 14;
      1. Federally Registered Pesticides. 2nd ed. North American Compendiums, Inc, Port Huron (MI)1993
        • Kanetoshi A
        • Katsura E
        • Ogawa H
        • Ohyama T
        • Kaneshima H
        • Miura T.
        Acute toxicity, percutaneous absorption and effects on hepatic mixed function oxidase activities of 2,4,4'-trichloro-2'-hydroxydiphenyl ether (Irgasan7DP300) and its chlorinated derivatives.
        Arch Environ Contamination Toxicology. 1992; 23: 91-98
        • Black JG
        • Howes D
        • Rutherford T.
        Percutaneous absorption and metabolism of Irgasan7DP300.
        Toxicology. 1975; 3: 33-47
        • Waaler SM
        • Rolla G
        • Skjorland KK
        • Ogaard B.
        Effects of oral rinsing with triclosan and sodium lauryl sulfate on dental plaque formation: a pilot study.
        Scand J Dental Res. 1993; 101: 192-195
        • Barkvoll P
        • Rolla G.
        Triclosan protects the skin against dermatitis caused by sodium lauryl sulphate exposure.
        J Clin Periodontol. 1994; 21: 717-719
        • Coleman EJ
        • Espositio A
        • Afflitto J
        • Gaffar A.
        Triclosan prevents SLS-cytotoxicity to human gingival fibroblasts.
        J Dental Res. 1993; 72: 1837
        • Ciba-Geigy Corporation, Inc
        Diphenyl compounds which inhibit arachidonic acid metabolism and their use in pharmaceutical compositions.
        1993 (US Patent 5,185,377)
        • Unilever, Inc
        Oral compositions containing Triclosan for the treatment of aphthous ulcer.
        Patent WO. 1994; (94/26258)
        • Unilever, Inc
        Use of triclosan for the manufacture of a medicament for the treatment of periodontitis. 1992 (Patent EP 0528468A1)
        • Meincke BE
        • Kranz RG
        • Lynch DL.
        Effect of Irgasan on bacterial growth and its adsorption into the cell wall.
        Microbios. 1980; 28: 133-147
        • Nissen HP
        • Ochs D.
        Triclosan. Cosmetics Toiletries. 1998; 113: 61-64
        • Sastzu M
        • Shimizu K
        • Noguchi N
        • Kono M.
        Triclosan-resistant Staphylococcus aureus.
        Lancet. 1993; 341 ([letter]): 20
        • McMurry LM
        • Oethinger M
        • Levy SB.
        Triclosan targets lipid synthesis.
        Nature. 1998; 394: 531-532
        • Tattawasart U
        • Maillard JY
        • Furr JR
        • Russell AD.
        Development of chlorhexidine and antibiotic resistance in Pseudomonas stutzeri.
        Proceedings of the 98th General Meeting of the American Society for Microbiology. May 1998; (Atlanta, Ga): 533
        • McMurry LM
        • Oethinger M
        • Levy SB.
        Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli.
        FEMS Micro Lett. 1998; 166: 305-309
        • Russell AD
        • Maillard JY
        • Furr JR.
        Possible link between bacterial resistance and use of antibiotics and biocides.
        Antimicrob Agents Chemother. 1998; 42: 2151
        • Heath RJ
        • Yuo YT
        • Shapiro MA
        • Olson E
        • Rock CO.
        Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis.
        J Biol Chem. 1998; 273: 30316-30320
        • Russell AD.
        Plasmids and bacterial resistance to biocide.
        J Appl Microbiol. 1997; 82: 155-165
        • Uhl S.
        Triclosan-resistant Staphylococcus aureus.
        Lancet. 1993; 342 ([letter]): 248
        • Sastzu M
        • Shimizu K
        • Noguchi N
        • Kono M.
        Triclosan-resistant Staphylococcus aureus -Author's Reply.
        Lancet. 1993; 342 ([letter]): 248
        • McDonnell G
        • Pretzer D.
        Action and targets of triclosan.
        ASM News. 1998; 64: 670-671
        • Cox AR.
        Efficacy of the antimicrobial agent triclosan in topical deodorant products: Recent Developments in vivo.
        J Soc Cosmetic Chem. 1987; 38: 223-231
        • Volpe AR
        • Petrone ME
        • De Vizio W
        • Davies RM.
        A Review of plaque, gingivitis, calculus and caries clinical efficacy studies with a dentifrice containing triclosan and PVM/MA copolymer.
        J Clin Dentistry Special Issue. 1993; 4: 31-41
        • Jones CL
        • Ritchie JA
        • Marsh PD
        • Van Der Ouderaa F.
        The Effect of long-term use of a dentifrice containing zinc citrate and a non-ionic agent on the oral flora.
        J Dental Res. 1988; 67: 46-50
        • Stephen KW
        • Saxton CA
        • Jones CL
        • Ritchie JA
        • Morrison T.
        Control of gingivitis and calculus by a dentifrice containing a zinc salt and triclosan.
        J Periodontol. 1990; 61: 674-679
        • Gehring W
        • Forssman T
        • Jost G
        • Gloor M.
        The germ-reducing effect of erythromycin and triclosan in atopic dermatitis.
        Aktuelle Dermatol. 1996; 22: 28-31
        • Ciba-Geigy Corporation
        Irgasan7 DP300: highly effective antimicrobial for hand disinfectants.
        (Document No. 2513E)1990 Oct 3
        • Jampani H
        • Lee A
        • Newman J
        • Jones R.
        A comprehensive comparison of the in vitro and in vivo antimicrobial effectiveness of triclosan, chlorhexidine, alcohol/chlorhexidine, and poloxamer iodine topical formulations.
        AJIC Am J Infect Control. 1998; 26 ([abstract]): 186
        • Ciba-Geigy Corporation
        Letter to W. Gilbertson and attachments.
        FDA Public Docket. 1995 Dec 14; (75N-183H)
        • The Soap and Detergent Association and The Cosmetic, Toiletry, and Fragrance Association
        Letter to W. Gilbertson and attachments.
        FDA Public Docket. 1995 June 13; (75N-183H)
        • The Soap and Detergent Association and The Cosmetic, Toiletry, and Fragrance Association
        Letter to W. Gilbertson and attachments.
        FDA Public Docket. 1995 Dec 14; (75N-183H)
        • The Soap and Detergent Association and The Cosmetic, Toiletry, and Fragrance Association
        Letter to W. Gilbertson and attachments.
        FDA Public Docket. 1995 Mar 15; (75N-183H)
        • Vischer WA
        • Regos J.
        Antimicrobial spectrum of Triclosan a broad spectrum antimicrobial agent.
        Zentralbl Baketeriol. 1974; 226: 376-389
        • Sehulster LM
        • Anderson RL.
        Susceptibility of glycopeptide-intermediate resistant Staphylococcus aureus (GISA) to surface disinfectants, hand washing chemicals, and a skin antiseptic.
        Proceedings of the 98th General Meeting of the American Society for Microbiology. May 1998; : 547
        • American Society of Testing and Materials
        E1174-94 Standard test method for evaluation of health care personnel handwash formulation.
        in: The annual book of standards. 11.05. ASTM, West Conshohocken (PA)1991: 480-482
        • Benson L
        • Bush L
        • LeBlanc D.
        Importance of neutralizers in the stripping fluid in a simulated healthcare personnel handwash.
        Infect Control Hosp Epidemiol. 1990; 11: 595-599
        • Bartzokas CA
        • Corkill JE
        • Makin T.
        Evaluation of the skin disinfecting activity and cumulative effect of chlorhexidine and triclosan handwash preparations on hands artificially contaminated with Serratia marcescens.
        Infect Control. 1987; 8: 163-167
        • Bartzokas CA
        • Gibson MF
        • Graham R
        • Pinder DC.
        A comparison of triclosan and chlorhexidine preparations with 60 per cent isopropyl alcohol for hygienic hand disinfection.
        J Hosp Infection. 1983; 4: 245-255
        • Sheena AZ
        • Stiles BE.
        Efficacy of germicidal hand wash agents against transient bacteria inoculated onto hands.
        J Food Protect. 1983; 46: 722-727
        • Stiles BE
        • Sheena AZ.
        Efficacy of germicidal hand wash agents in use in a meat processing plant.
        J Food Protect. 1987; 50: 289-295
        • Bartzokas CA
        • Corkill JE
        • Makin T
        • Parry E.
        Comparative evaluation of the immediate and sustained antibacterial action of two regimens, based on triclosan- and chlorhexidine-containing handwash preparations, on volunteers.
        Epidemiol Infect. 1987; 98: 337-344
        • Faoagali J
        • Fong J
        • George N
        • Mahoney P
        • O'Rourke V.
        Comparison of the immediate, residual, and cumulative antibacterial effects of Novaderm R, Novascrub R, Betadine Surgical Scrub, Hibiclens, and liquid soap.
        AJIC Am J Infect Control. 1995; 23: 337-343
        • Bartzokas CA
        • Corkill JE
        • Makin T
        • Pinder DC.
        Assessment of the remanent antibacterial effect of a 2% triclosan-detergent preparation on the skin.
        J Hyg Cambridge. 1983; 91: 521-528
        • Huntington Laboratories, Inc
        Letter to W. Gilbertson and attachments.
        FDA Public Docket. 1995 Dec 13; (75N-183H)
        • Mbithi JN
        • Springthorpe VS
        • Sattar SA.
        Comparative in vivo efficiencies of hand-washing agents against hepatitis A Virus (HM-175) and poliovirus type 1 (Sabin).
        Appl Environ Microbiol. 1993; 59: 3463-3469
        • Bellamy K
        • Alcock R
        • Babb JR
        • Davies JG
        • Ayliffe GA.
        A test for the assessment of “hygienic” hand disinfection using rotavirus.
        J Hosp Infect. 1993; 24: 201-210
        • Zafar AB
        • Butler RC
        • Reese DJ
        • Gaydos LA
        • Mennonna PA.
        Use of 0.3% triclosan (Bacti-stat*) to eradicate an outbreak of methicillin-resistant Staphylococcus aureus in a neonatal nursery.
        AJIC Am J Infect Control. 1995; 23: 200-208
        • Marshall PJ.
        Use of triclosan to reduce the incidence of M.R.S.A.
        Proceedings of the National Conference of the Australian Infection Control Association. May 7-9, 1997;
        • Webster J.
        Hand-washing in a neonatal intensive care unit.
        Aust Coll Midwives Inc J. 1991; 4: 25-27
        • Webster J.
        Hand washing in a neonatal intensive care nursery: product acceptability and effectiveness of chlorhexidine gluconate 4% and triclosan 1%.
        J Hosp Infect. 1992; 21: 137-141
        • Webster J
        • Faogali JL
        • Cartwright D.
        Elimination of methicillin-resistant Staphylococcus aureus from a neonatal intensive care unit after hand washing with triclosan.
        J Paediatr Child Health. 1994; 30: 59-64
        • Tuffnell DJ
        • Croton RS
        • Hemingway DM
        • Hartely MN
        • Wake PN
        • Garvey RJP.
        Methicillin resistant Staphylococcus aureus ; the role of antisepsis in the control of an outbreak.
        J Hosp Infect. 1987; 10: 255-259
        • Brady LM
        • Thomson M
        • Plamer MA
        • Harkness JL.
        Successful control of endemic MRSA in a cardiothoracic surgical unit.
        Med J Aust. 1990; 1552: 240-245
        • Wenzel RP
        • Pfaller MA.
        Hand washing: efficacy versus acceptance. A brief essay.
        J Hosp Infect. 1991; 18: 65-68